352. Chris Kiple, CEO of Solius Labs

Today, I'm joined by Chris Kiple, CEO of Solius Labs.   A decade in development, Solius's FDA-cleared UVB light therapy device personalizes dosage by skin type, aiming to replicate the benefits of sunlight while minimizing carcinogenic risk.    In this episode, we discuss sunlight as a foundational pillar of health and longevity.    We also cover: Why sun avoidance is deadlier than smoking Designing a skin scanner for personalized UVB dosing Moving UVB therapy from clinical dermatology to consumer health Subscribe to the podcast → insider.fitt.co/podcast  Subscribe to our newsletter → insider.fitt.co/subscribe  Follow us on LinkedIn → linkedin.com/company/fittinsider    Website: www.solius.com  Instagram: https://www.instagram.com/soliuslabs    -   The Fitt Insider Podcast is brought to you by EGYM. Visit EGYM.com  to learn more about its smart fitness ecosystem for fitness and health facilities.   Fitt Talent: https://talent.fitt.co/  Consulting: https://consulting.fitt.co/  Investments: https://capital.fitt.co/    Chapters: (00:00) Introduction (00:29) Swedish longevity study (01:20) Chris background and Solius overview (02:05) UVB light therapy foundation (04:00) 10-year development and timing (05:07) Sun exposure evolution and skin type (08:10) Solius technology and personalized dosing (09:35) Skin scanning and dosing mechanism (11:00) FDA clearance and safety focus (12:40) OTC vs. prescription positioning (14:15) Safety risk contextualization (15:42) Healthcare partnerships strategy (17:50) Dermatology focus (19:00) Orthopedic and cardiovascular applications (20:32) Longevity clinic partnerships (22:35) Swedish and UK biobank studies (26:00) Hormone production benefits (27:20) Cardiovascular and nitric oxide improvements (28:30) Microbiome diversity impact (31:15) Platform evolution and future devices (33:20) Team-building and advisory board (34:45) Listening to early users (36:40) Where to find (38:07) Conclusion